ArticleBMC infectious diseases2026
Vulvovaginal candidiasis and antifungal susceptibility pattern of isolated Candida spp. among women in Aden Governorate, Yemen.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epidemiology, Diagnostics and Therapy of Vulvovaginal Fungal Infections.Pathogens (Basel, Switzerland) · 2026Review
- Vulvovaginal candidiasis among Yemeni women: prevalence of Candida species, biofilm formation rates, antifungal susceptibility patterns, and biofilm-associated genes ALS1 and HWP1.BMC microbiology · 2026Article
- Association of TLR4 Polymorphisms with Increased Susceptibility to Recurrent Vulvovaginal Candidiasis in Greek Women.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVulvovaginal Candidiasis is a complicated inflammatory infectious disease of the female genital tract caused by the genus Candida. Most studies dealing with VVC in Yemen did not involve both risk factors and antifungal sensitivity. So, this study was performed to evaluate risk factors contributing to VVC and to evaluate the antifungal susceptibility patterns of Candida spp. among women in Aden, Yemen.
methodsOne hundred and two women were enrolled in this cross-sectional study. Two high vaginal swabs were collected, tested microscopically, and inoculated in SDA. A chromogenic medium was used to identify and differentiate Candida species. Six available antifungal agents were used for sensitivity testing included: Itraconazole, Fluconazole, Ketoconazole, Clotrimazole, Nystatin and Miconazole by disc diffusion method. The data was finally analyzed by using SPSS software (Version 21).
resultsA total of 102 women were included in this study. The mean age was 27.36 ± 7.7 years, with a range of 16–47 years. The overall frequency of VV among women was 39.2%. The highest rate was 44.9% (22/49) in the age group < 25 years. Five species of Candida were isolated, with C. albicans being the most frequent (55%), followed by C. krusei (17.5%), C. glabrata (12.5%), C. tropicalis (10%) and C. parapsilosis (5%). Symptom severity was significantly associated with VVC (p = 0.0001), whereas the association with pregnancy did not reach statistical significance (p = 0.066). In terms of antifungal susceptibility testing, the overall resistance was 20% to Clotrimazole, 15% to Nystatin, 7.5% to both Ketoconazole and Miconazole and the lowest resistance rate (2.5%) was to Fluconazole. All five isolated species were 100% sensitive to Itraconazole.
conclusionIt can be concluded from this study that the overall frequency of VVC among women in Aden-Yemen is higher than that reported among Yemeni women, while slightly lower than that reported globally. The infection was high among women in the age group < 25 years. C. albicans and C. krusei were the most frequent species. The pregnancy may increase the risk of VVC. Resistance was found to Clotrimazole, Nystatin, Ketoconazole, Miconazole, and Fluconazole, while no resistance was detected to Itraconazole among those species. The resistance among non-albicans Candida (NAC) species has increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.